ABT-229 ( 1) is an erythromycin derivative that lacks antibacterial activity but is a potent motilin receptor agonist. 1 As such, 1 is a member of the class of compounds known as motilides, 2 which have been tested in clinical trials as potential prokinetic agents for the treatment of diabetic gastroparesis, gastroesophageal reflux disease, and functional dyspepsia.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.